Drug intelligence / Profile preview

CCP-08

Development stage: Discontinued
Lead developer: Vernalis
Modality: Small Molecules
Administration: Oral

Overview

CCP-08 is an **extended-release liquid formulation developed as a prescription medication targeting the U.S. cough and cold market**[1][3][7][11][12][14]. It was designed as a long-acting equivalent to existing immediate-release cough/cold treatments, utilizing Tris Pharma's OralXR+ technology for sustained symptom relief[3][7][11]. CCP-08 was developed under a collaboration between Vernalis and Tris Pharma, focused on expanding the portfolio of extended-release cough and cold medications[3][12]. The precise active ingredients and mechanism of action are not disclosed in public sources, but the product's profile aligns with antitussive and/or expectorant therapies aimed at symptomatic relief for upper respiratory conditions.

Brand names: CCP-08CCP08CCP 08
Other names: CCP-08CCP08CCP 08

Beyond the preview

Go deeper on CCP-08.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CCP-08.

Explore the full profile